A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of BioScrip Inc (NASDAQ:BIOS) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on July 12, 2016 and NASDAQ:BIOS investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/16/2016 -- The Shareholders Foundation announced that a deadline is coming up on July 12, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of BioScrip Inc (NASDAQ:BIOS) between November 9, 2012 and November 6, 2013.
Investors who purchased a significant amount of shares of BioScrip Inc (NASDAQ:BIOS) between November 9, 2012 and November 6, 2013, have certain options and should contact the Shareholders Foundation by email at email@example.com or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the BioScrip Inc (NASDAQ:BIOS) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/bioscrip-inc-nasdaq-bios-investor-securities-class-action-lawsuit-09302013
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is July 12, 2016. The class action administrator for this case is A.B. Data Ltd.
The lawsuit was originally filed in the U.S. District Court for the Southern District of New York against BioScrip Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between August 8, 2011 and September 20, 2013. According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of BioScrip Inc (NASDAQ:BIOS) between August 8, 2011 and September 20, 2013, that BioScrip Inc and certain of its officers and directors violated federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. More specifically, the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that BioScrip Inc improperly distributed the product Exjade through its specialty pharmacy operations, that BioScrip Inc was in violation of certain federal and state laws and regulations, and that as a result of the foregoing BioScrip Inc's statements were materially false and misleading at all relevant times.
Those who purchased shares of BioScrip Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego